AR109295A1 - Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina - Google Patents

Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina

Info

Publication number
AR109295A1
AR109295A1 ARP170102212A ARP170102212A AR109295A1 AR 109295 A1 AR109295 A1 AR 109295A1 AR P170102212 A ARP170102212 A AR P170102212A AR P170102212 A ARP170102212 A AR P170102212A AR 109295 A1 AR109295 A1 AR 109295A1
Authority
AR
Argentina
Prior art keywords
independently
alkyl
deuterium
hydroxy
amino
Prior art date
Application number
ARP170102212A
Other languages
English (en)
Inventor
Yingjun Zhang
Shengtian Cao
Shengqiang Pan
Shaohui Xiong
Junwen Wu
Xinye Yang
Xiaojun Wang
Original Assignee
Sunshine Lake Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunshine Lake Pharma Co Ltd filed Critical Sunshine Lake Pharma Co Ltd
Publication of AR109295A1 publication Critical patent/AR109295A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Compuestos tricíclicos que contienen nitrógeno que actúan como moduladores del FXR, o un estereoisómero, un isómero geométrico, un tautómero, un N-óxido, un hidrato, un solvato, un metabolito, una sal aceptable para uso farmacéutico o un profármaco del mismo, y el uso del compuesto para el tratamiento de enfermedades y/o condiciones mediadas por FXR. Además una composición farmacéutica que contiene el compuesto descripto en la presente y un método para el tratamiento de enfermedades y/o condiciones mediadas por FXR que comprende la administración del compuesto o la composición farmacéutica del mismo. Reivindicación 1: Un compuesto que presenta la fórmula (1), o un esteroisómero, un isómero geométrico, un tautómero, un N-óxido, un hidrato, un solvato, un metabolito, una sal aceptable para uso farmacéutico o un profármaco del mismo, donde: T es -NH-, -O-, -S-, -C(=O)- o -CH₂-; cada uno de X e Y es de modo independiente un enlace, -O-, -S(=O)ₜ, -NRˣ-, -CRʸRᶻ- o -C(=O)-, o -X-Y- es -CHRʰ-CHRᵏ- o -CRʸ=CRᶻ-; cada Rˣ es de modo independiente hidrógeno, deuterio, alquilo, aminoalquilo, haloalquilo, cicloalquilo, heterociclilo, arilo, arilo halo sustituido o arilalquilo; cada uno de Rʸ y Rᶻ es de modo independiente hidrógeno, deuterio, F, Cl, Br, I, hidroxi, amino, nitro, ciano, alquilo, haloalquilo, hidroxialquilo, aminoalquilo, alcoxi, alquilamino, alquenilo, alquinilo, cicloalquilo, heterociclilo, arilo, arilo halo sustituido o arilalquilo; o Rʸ y Rᶻ junto con el átomo de carbono adyacente al que están unidos, de modo independiente y opcional forma un anillo de cicloalcano o un anillo heterocíclico, y donde el anillo de cicloalcano y anillo heterocíclico es de modo independiente y opcionalmente sustituido con sustituyentes seleccionados de F, Cl, Br, I, hidroxi, amino, nitro, ciano, metilo, etilo, isopropilo y trifluorometilo; cada Rʰ y Rᵏ es de modo independiente hidrógeno, deuterio, F, Cl, Br, I, hidroxi, amino, nitro, ciano, metilo, etilo, isopropilo o trifluorometilo; o Rʰ y Rᵏ, junto con el átomo de carbón al cual están unido, forman un anillo de cicloalcano o un anillo heterocíclico, donde el anillo cicloalcano y anillo heterocíclico es de modo independiente y opcionalmente sustituido por sustituyentes seleccionados de F, Cl, Br, I, hidroxi, amino, nitro, ciano, metilo, etilo, isopropilo y trifluorometilo; cada Rᵃ y Rᵇ es de modo independiente hidrógeno, deuterio o C₁₋₃ alquilo; cada Rᶜ es de modo independiente hidrógeno, deuterio, F, Cl, Br, I, oxo, hidroxi, amino, nitro, ciano, metilo, etilo, n-propilo, isopropilo, difluorometilo, trifluorometilo, difluorometoxi, trifluorometoxi, hidroximetilo, aminometilo, metilamino, dimetilamino, metoximetilo, isopropoximetilo, vinilo, etinilo, ciclopropilo, ciclobutilo, ciclopentilo, ciclohexilo, azetidinilo, tetrahidrofuranilo, pirrolidinilo, piperidinilo, piperazinilo, tetrahidropiranilo, morfolinilo, tiomorfolinilo, fenilo, tiazolilo, tienilo, oxazolilo, triazolilo, tetrazolilo, piridinilo, pirimidinilo, -COOH, -C(=O)O-C₁₋₃ alquilo, -C(=O)NHS(=O)₂-C₁₋₃ alquilo, -C(=O)NHS(=O)₂-fenilo, -C(=O)NH-C₁₋₃ alquilen-S(=O)₂OH, -C(=O)NH-C₁₋₃ alquilen-C(=O)OH, -S(=O)₂NH₂, -S(=O)₂OH, -S(=O)₂-C₁₋₃ alquilo, -C(=O)NH₂ o -C(=O)N(CH₃)₂; cada R¹ es de modo independiente hidrógeno, deuterio, F, Cl, Br, I, hidroxi, amino, nitro, ciano, alquilo, haloalquilo, hidroxialquilo, aminoalquilo, alcoxi, alquilamino, haloalcoxi, alcoxialquilo, alquenilo, alquinilo, cicloalquilo, cicloalcoxi, cicloalquilalquilo, heterociclilo, heterociclilalquilo, arilo, arilo halo sustituido, arilalquilo, heteroarilo, -L¹-C(=O)OR⁸, -L¹-S(=O)ₜR⁹, -O-L²-C(=O)OR⁸, -O-L²-S(=O)ₜR⁹, -C(=O)NR¹⁰R¹¹, -C(=O)N(R¹⁰)S(=O)₂R⁹, -C(=NR¹⁰)NR¹⁰R¹¹, -C(=O)N(R¹⁰)-L³-S(=O)₂OR⁸, -C(=O)N(R¹⁰)C(=O)OR⁸ o -C(=O)N(R¹⁰)-L³-C(=O)OR⁸; o dos R¹ adyacentes, junto con los átomos del anillo al cual están unidos, de modo independiente y opcional forman un anillo carbocíclico, anillo heterocíclico, anillo aromático o anillo heteroaromático, y donde cada R¹ está de modo independiente y opcionalmente sustituido por uno o más R¹²; cada R⁸ es de modo independiente hidrógeno, deuterio, alquilo, aminoalquilo, alquenilo, alquinilo, haloalquilo, cicloalquilo, heterociclilo o arilo; cada R⁹ es de modo independiente hidrógeno, deuterio, hidroxi, amino, alquilo, aminoalquilo, alquenilo, alquinilo, haloalquilo, cicloalquilo, heterociclilo, arilo o -NR¹⁰R¹¹; cada R¹⁰ y R¹¹ es de modo independiente hidrógeno, deuterio, alquilo, aminoalquilo, alquenilo, alquinilo, haloalquilo, cicloalquilo, heterociclilo o arilo; o R¹⁰ y R¹¹, junto con el átomo de nitrógeno al cual están unido, de modo independiente y opcional forman un anillo heterocíclico o anillo heteroaromático; cada R¹² es de modo independiente hidrógeno, deuterio, F, Cl, Br, I, oxo, hidroxi, amino, nitro, ciano, alquilo, haloalquilo, alcoxi, alquilamino, alquenilo, alquinilo, cicloalquilo, heterociclilo, arilo o heteroarilo; cada L¹ es de modo independiente un enlace, -NH-, -C(=O)-, C₁₋₃ alquileno, C₂₋₄ alquenileno o C₂₋₄ alquinileno; cada L² es de modo independiente C₁₋₃ alquileno, C₂₋₄ alquenileno o C₂₋₄ alquinileno; cada L³ es de modo independiente un enlace o C₁₋₃ alquileno; Z es un compuesto seleccionado del grupo de fórmulas (2); cada L es de modo independiente un enlace, -O-, -S-, -NH-, -CH₂-, -CH₂-CH₂-, -O-CH₂-, -O-CH₂-CH₂- o -CH₂-O-CH₂-; cada R², R³, R⁴, R⁵ y R⁶ es de modo independiente hidrógeno, deuterio, F, Cl, Br, I, hidroxi, amino, nitro, ciano, C₁₋₃ alquilo, C₁₋₃ haloalquilo, C₁₋₃ alcoxi or C₁₋₃ haloalcoxi; cada R⁷ es de modo independiente hidrógeno, deuterio, F, Cl, Br, I, hidroxi, amino, nitro, ciano, C₁₋₆ alquilo, C₁₋₆ hidroxialquilo, C₁₋₆ haloalquilo, C₁₋₆ alcoxi, C₁₋₆ alquilamino, C₁₋₆ alcoxi-C₁₋₆ alquilo, C₃₋₆ cicloalquilo o C₂₋₆ heterociclilo, y donde el C₃₋₆ cicloalquilo y C₂₋₆ heterociclilo está de modo independiente y opcionalmente sustituido por sustituyentes seleccionados de F, Cl, Br, I, hidroxi, amino, nitro y ciano; m es 0, 1, 2, 3 ó 4; n es 0, 1 ó 2; y cada t es de modo independiente 0, 1 ó 2; con la condición que un compuesto que tiene la fórmula (I) no sea un compuesto seleccionado del grupo de fórmulas (3).
ARP170102212A 2016-08-05 2017-08-04 Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina AR109295A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610640043 2016-08-05

Publications (1)

Publication Number Publication Date
AR109295A1 true AR109295A1 (es) 2018-11-14

Family

ID=61072781

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102212A AR109295A1 (es) 2016-08-05 2017-08-04 Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina

Country Status (11)

Country Link
US (1) US10562910B2 (es)
EP (1) EP3494118B1 (es)
JP (1) JP6983225B2 (es)
KR (1) KR102368298B1 (es)
CN (1) CN107686486B (es)
AR (1) AR109295A1 (es)
AU (1) AU2017306605B2 (es)
CA (1) CA3030377C (es)
ES (1) ES2950412T3 (es)
TW (1) TW201808283A (es)
WO (1) WO2018024224A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
PE20170694A1 (es) 2014-10-06 2017-05-26 Exicure Inc Compuestos anti-tnf
ES2886766T3 (es) 2015-03-31 2021-12-20 Enanta Pharm Inc Derivados del ácido biliar como agonistas de FXR/TGR5 y métodos de uso de estos
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
CN109906223A (zh) 2016-10-04 2019-06-18 英安塔制药有限公司 异噁唑类似物作为fxr激动剂及其使用方法
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
US20180280394A1 (en) 2017-03-28 2018-10-04 Gilead Sciences, Inc. Methods of treating liver disease
AU2018360575A1 (en) * 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CR20210385A (es) 2019-01-15 2021-09-14 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
KR20210129128A (ko) 2019-02-19 2021-10-27 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN110028443B (zh) * 2019-05-29 2022-03-04 济南周行医药科技有限公司 一种调节fxr活性的三环化合物类药物中间体的制备方法
AU2020319052A1 (en) 2019-07-23 2022-01-27 Novartis Ag Combination treatment of liver diseases using FXR agonists
US20220265614A1 (en) 2019-07-23 2022-08-25 Novartis Ag Treatment comprising fxr agonists
WO2021044287A1 (en) 2019-09-03 2021-03-11 Novartis Ag Treatment of liver disease or disorder comprising actrii receptor antagonists
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
WO2021064575A1 (en) 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
US20230002400A1 (en) * 2019-11-29 2023-01-05 Sunshine Lake Pharma Co., Ltd. Amorphous form of nitrogen-containing tricyclic compound and use thereof
CN112876490A (zh) * 2019-11-29 2021-06-01 广东东阳光药业有限公司 含氮三环化合物的晶型及其用途
JP2023505116A (ja) * 2019-11-29 2023-02-08 ▲広▼▲東▼▲東▼▲陽▼光▲薬▼▲業▼有限公司 三環式含窒素化合物の結晶形及びその用途
CN112876493B (zh) * 2019-11-29 2023-05-09 广东东阳光药业有限公司 含氮三环化合物的盐及其用途
US20230060422A1 (en) 2019-12-20 2023-03-02 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
WO2023061468A1 (zh) * 2021-10-15 2023-04-20 广东东阳光药业有限公司 含氮三环化合物的新晶型及其用途
WO2023061477A1 (zh) * 2021-10-15 2023-04-20 广东东阳光药业有限公司 含氮三环化合物的新晶型及其用途
CN115974884A (zh) * 2021-10-15 2023-04-18 广东东阳光药业有限公司 含氮三环化合物的新晶型及其用途

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US801249A (en) * 1904-03-10 1905-10-10 Edward Keagy Concrete-block mold.
WO2000037077A1 (en) 1998-12-23 2000-06-29 Glaxo Group Limited Assays for ligands for nuclear receptors
DK1182200T3 (da) 1999-06-03 2005-12-27 Nippon Suisan Kaisha Ltd Tricykliske kondenserede heterocykliske forbindelser, fremgangsmåde til fremstilling deraf og anvendelse deraf
ATE381542T1 (de) 2001-08-13 2008-01-15 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
AU2003290700A1 (en) 2002-11-22 2004-06-18 Smithkline Beecham Corporation Farnesoid x receptor agonists
ES2374165T3 (es) 2005-12-19 2012-02-14 Glaxosmithkline Llc Agonistas del receptor x farnesoide.
ES2452031T3 (es) 2006-02-03 2014-03-31 Eli Lilly & Company Compuestos y procedimientos para modular receptores FX
JP2007230909A (ja) 2006-03-01 2007-09-13 Univ Of Tokyo 置換イソキサゾール誘導体
BRPI0711875A2 (pt) 2006-05-24 2012-01-10 Lilly Co Eli compostos e métodos para modular os fxr
DK2029547T3 (da) * 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
EP1894928A1 (en) * 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP2121621B1 (en) * 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
CN101977505A (zh) * 2007-06-13 2011-02-16 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
AU2008270784A1 (en) * 2007-07-02 2009-01-08 Glaxosmithkline Llc Farnesoid X receptor agonists
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
EP2128158A1 (en) * 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
WO2012087520A1 (en) 2010-12-20 2012-06-28 Irm Llc Compositions and methods for modulating farnesoid x receptors
CN103391937A (zh) 2010-12-20 2013-11-13 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CN104513213A (zh) 2013-09-28 2015-04-15 山东亨利医药科技有限责任公司 Fxr激动剂
CN104045635A (zh) 2014-06-23 2014-09-17 华东理工大学 3,4,5-三取代异恶唑类化合物及其用途
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3233083A1 (en) 2014-12-18 2017-10-25 Novartis AG Azabicyclooctane derivatives as fxr agonists for use in the treatment of liver and gastrointestinal diseases
SG11201704770YA (en) * 2014-12-22 2017-07-28 Akarna Therapeutics Ltd Fused bicyclic compounds for the treatment of disease
TWI698430B (zh) * 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN106146483A (zh) 2015-04-23 2016-11-23 上海迪诺医药科技有限公司 杂环类法尼酯衍生物x受体调节剂
JP6691552B2 (ja) * 2015-04-30 2020-04-28 ノバルティス アーゲー ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
CN107021958A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
CN108602811B (zh) 2016-02-01 2021-11-16 轩竹生物科技有限公司 Fxr受体激动剂
CN107021957A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
TW201741307A (zh) 2016-02-22 2017-12-01 艾洛斯生物製藥公司 Ｆｘｒ調節劑及其使用方法
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189651A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201155A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
US10138228B2 (en) 2016-05-18 2018-11-27 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use therof
WO2017201150A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
US10793568B2 (en) 2016-08-23 2020-10-06 Ardelyx, Inc. Hormone receptor modulators for treating metabolic conditions and disorders
WO2018059314A1 (zh) 2016-09-28 2018-04-05 四川科伦博泰生物医药股份有限公司 氮杂双环衍生物及其制备方法和用途
CN109906223A (zh) 2016-10-04 2019-06-18 英安塔制药有限公司 异噁唑类似物作为fxr激动剂及其使用方法
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
CN108218852A (zh) 2016-12-15 2018-06-29 宁波百纳西药业有限公司 一种螺环化合物、其制备方法、组合物及用途
CN109071468B (zh) 2017-01-20 2022-09-02 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
CN108341822B (zh) 2017-01-23 2021-04-16 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和应用
CN108264506B (zh) 2018-01-17 2021-01-26 中国药科大学 异黄酮衍生物、其制备方法和医药用途
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用

Also Published As

Publication number Publication date
JP2019524784A (ja) 2019-09-05
CA3030377A1 (en) 2018-02-08
CN107686486B (zh) 2020-12-22
CN107686486A (zh) 2018-02-13
EP3494118B1 (en) 2023-06-21
CA3030377C (en) 2023-12-12
AU2017306605A1 (en) 2019-02-14
JP6983225B2 (ja) 2021-12-17
US20190169203A1 (en) 2019-06-06
KR20190035766A (ko) 2019-04-03
WO2018024224A1 (en) 2018-02-08
AU2017306605B2 (en) 2021-08-05
US10562910B2 (en) 2020-02-18
TW201808283A (zh) 2018-03-16
EP3494118A1 (en) 2019-06-12
EP3494118A4 (en) 2020-02-26
ES2950412T3 (es) 2023-10-09
KR102368298B1 (ko) 2022-02-28

Similar Documents

Publication Publication Date Title
AR109295A1 (es) Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina
AR116993A2 (es) Compuestos heterociclos bicíclicos y sus usos en terapia
AR103574A1 (es) Compuestos tricíclicos y usos de lo mismos en medicina
DOP2016000281A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer
PE20190709A1 (es) Derivado de pirazolopiridinaque tiene el efecto agonista del receptor de glp-1
UY36766A (es) Derivados de sulfamoilarilamida ciclados como inhibidores del vhb, procesos de preparación y composiciones farmacéuticas que los contienen
AR097024A1 (es) Derivados sustituidos de quinazolin-4-ona
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR100691A1 (es) Esteroides neuroactivos, composiciones, y usos de los mismos
AR090994A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
MX366123B (es) Sulfamoil-arilamidas y el uso de las mismas como medicamentos para el tratamiento de la hepatitis b.
MX2015014033A (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR094300A1 (es) Derivados de quinolonas
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
AR094550A1 (es) Inhibidores de btk
AR091156A1 (es) Nucleosidos de espirooxetano de uracilo
AR107042A1 (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
AR096543A1 (es) INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES
AR092809A1 (es) 3,5-diaminopirazol como inhibidor de quinasa
AR097756A1 (es) Derivados de fenilalanina sustituidos
CR20190261A (es) Inhibidores de la tirosina quinasa de bruton